According to Aeterna Zentaris's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.14224. At the end of 2021 the company had a P/E ratio of -0.2101.
Year | P/E ratio | Change |
---|---|---|
2021 | -0.2101 | 47.37% |
2020 | -0.1425 | -94.75% |
2019 | -2.71 | -122.4% |
2018 | 12.1 | -675.19% |
2017 | -2.11 | 41.06% |
2016 | -1.49 | 463.35% |
2015 | -0.2652 | -88.4% |
2014 | -2.29 | -139.18% |
2013 | 5.83 | -337.48% |
2012 | -2.46 | -53.74% |
2011 | -5.31 | -5.93% |
2010 | -5.65 | 199.68% |
2009 | -1.88 | 414.58% |
2008 | -0.3661 | -85.59% |
2007 | -2.54 | -140.15% |
2006 | 6.33 | -71.46% |
2005 | 22.2 | -138.61% |
2004 | -57.4 | 777.57% |
2003 | -6.54 | -18.09% |
2002 | -7.99 | -90.42% |
2001 | -83.4 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() Novartis NVS | 28.4 | -2,585.21% | ๐จ๐ญ Switzerland |
![]() Sanofi SNY | 19.0 | -1,762.84% | ๐ซ๐ท France |
![]() Bristol-Myers Squibb BMY | 25.1 | -2,297.38% | ๐บ๐ธ USA |
![]() Spectrum Pharmaceuticals
SPPI | -1.09 | -4.52% | ๐บ๐ธ USA |
![]() Halozyme Therapeutics HALO | 24.3 | -2,228.05% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.